How to ensure the continued resurgence of tuberculosis

Lancet

Volumn 347, Issue 8995, 1996, Pages 175-177

  Reichman, Lee B ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFATER; SPARFLOXACIN; TUBERCULOSTATIC AGENT;

DRUG INDUSTRY; GOVERNMENT; HUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; SHORT SURVEY; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

EID: 0030041541     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90348-7     Document Type: Article

References (23)

1. Anonymous. Tuberculosis: a global emergency. World Health Forum 1993; 14: 438.
2. Anonymous. WHO Tuberculosis Programme. Analysis of 1994 obligations and proposed budget for 1995. Geneva: WHO/TB/TRAC 95.7, 1995.
3. US Congress, Office of Technology Assessment. The continuing challenge of tuberculosis, OTR H574. Washington, DC: US Government Printing Office, 1993: 91-106.
4. Bloom BR, Murray CJL. Tuberculosis: commentary on a reemergent killer. Science 1992; 257: 1055-64.
5. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis, morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-26.
6. Moulding T, Dutt A, Reichman LB. Fixed-dose combinations of antituberculosis medication to prevent drug resistance. Ann Intern Med 1995; 122: 951-54.
7. Binya T, Lizhen Z, Fengying A. A clinical comparative study of Chinese made rifapentine on chemotherapy of tuberculosis (follow-up results after 3 years), National Cooperative Group on the Clinical Study of Rifapentine. Chinese J Antibiotics 1992; 7: 313-22.
8. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144: 745-49.
9. Anonymous. Tuberculosis morbidity - United States 1994. MMWR 1995; 44: 387-95.
10. Anonymous. Cases of selected notifiable diseases, United States 44th week. MMWR 1995; 44: 835.
11. Frieden TR, Fujiwara PI, Washko RM, Hamburg MJ. Tuberculosis in New York City: turning the tide. N Engl J Med 1995; 333: 299-303.
12. Anonymous. Tuberculosis morbidity United States 1994. MMWR 1995; 44: 387-95.
13. Reichman LB. The U shaped curve of concern. Am Rev Respir Dis 1991; 144: 741-42.
14. National Tuberculosis Association and the US Public Health Service Tuberculosis Program. The Arden House Conference on Tuberculosis 1960. Washington DC: US Government Printing Office, 1961: Department of Health, Education, and Welfare Public Health Service Publication ML 784.
15. Hearing before the Subcommittee on Public Health and Government of the Committee on Interstate and Foreign Commerce, House of Representatives on Hr 14030, April 27. Washington, DC: US Government Printing Office, 1972: 71-75, 89-91.
16. Comstock G, Cauthen G. Epidemiology of tuberculosis. In: Reichman LB, Hershfield E, eds. Tuberculosis: a comprehensive international approach. New York: Marcel Dekker, 1993: 23-48.
17. Starke JR, Jacobs RF, Jareb J. Resurgence of tuberculosis in children. J Pediatrics 1992; 120: 839-55.
18. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-26.
19. Horton R. Towards the elimination of tuberculosis. Lancet 1995; 346: 790.
20. Waring JJ. Impact of modern therapy on tuberculosis. JAMA 1956; 161: 1368-71.
21. Driver CR, Valway SE, Morgan WM, Onorato IM, Castro KG. Transmission of Mycobacterium tuberculosis associated with air travel. JAMA 1994; 272: 1031-35.
22. Ridzon R. An outbreak of drug resistant tuberculosis in a California high school. Am J Respir Crit Care Med 1995; 151: A665.
23. United States General Accounting Office. Tuberculosis cases in five cities 1995. Washington, DC: GAO/HEHS-95-11, 1995.